X4 Pharmaceuticals, Inc. Share Price & Technical Analysis
XFOR · $4.04 (0.00%)
Healthcare / Biotechnology
$4.04
0.00%
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections,…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-2% return in May, 3% avg return in past 3 year May month.
4% return in 2026, 2% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -10% | -8% | 24% | 0% | -2% | – | – | – | – | – | – | – | 4% |
| 25 | -5% | -39% | -42% | -39% | -17% | -46% | -11% | 138% | -8% | 18% | -10% | 11% | -49% |
| 24 | -8% | 23% | 42% | -21% | -11% | -42% | 31% | -10% | -4% | -25% | -22% | 86% | 40% |
| 23 | 2% | -10% | -5% | 63% | 37% | -4% | -8% | -29% | -15% | -26% | -1% | 11% | 14% |
| 22 | -14% | -27% | 16% | -30% | -5% | -21% | 29% | -22% | 76% | 7% | -22% | -32% | -44% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$407.46M
P/E ratio
—
52W high
$4.83
52W low
$1.35
Volume
1,77,155
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is X4 Pharmaceuticals, Inc. share price today?
- X4 Pharmaceuticals, Inc. (XFOR) last traded around $4.04 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does XFOR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for XFOR. Download the app for real-time alerts.
- How can I analyze X4 Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.